These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 7672707)
21. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807 [TBL] [Abstract][Full Text] [Related]
22. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Crotzer DR; Wolf JK; Gano JB; Gershenson DM; Levenback C Gynecol Oncol; 2007 May; 105(2):399-403. PubMed ID: 17292457 [TBL] [Abstract][Full Text] [Related]
23. Ifosfamide combination regimens for soft-tissue sarcoma. Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695 [TBL] [Abstract][Full Text] [Related]
24. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. Sutton GP; Blessing JA; Homesley HD; Malfetano JH Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017 [TBL] [Abstract][Full Text] [Related]
25. Has "MAID" made it in the management of high-risk soft-tissue sarcoma? O'Sullivan B; Bell RS Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):915-6. PubMed ID: 12829123 [No Abstract] [Full Text] [Related]
26. A case of a patient diagnosed with malignant mixed Müllerian tumor of the ovary who conceived after conservative surgery and adjuvant chemotherapy. Shibahara H; Wakimoto E; Mitsuo M; Ogasawara T; Takemura T; Koyama K Gynecol Oncol; 1997 May; 65(2):363-5. PubMed ID: 9159353 [TBL] [Abstract][Full Text] [Related]
27. Cisplatin, doxorubicin, and cyclophosphamide (PAC) in the treatment of mixed mesodermal tumor of the ovary. Wheelock J; Hancock K; Smith K Cancer Treat Rep; 1987 Dec; 71(12):1275-6. PubMed ID: 3690537 [No Abstract] [Full Text] [Related]
28. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425 [TBL] [Abstract][Full Text] [Related]
29. Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience. Ishiyama Y; Inakawa T; Yoshino M; Nishimura K; Horiuchi T; Ishihara H; Toki D; Kondo T Anticancer Res; 2024 Jul; 44(7):3213-3220. PubMed ID: 38925814 [TBL] [Abstract][Full Text] [Related]
31. Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Simon SR; Wang SE; Uhl M; Shackney S Gynecol Oncol; 1991 May; 41(2):161-6. PubMed ID: 2050307 [TBL] [Abstract][Full Text] [Related]
32. [Soft tissue sarcoma: postoperative chemotherapy]. Goto T; Kosaku H; Kobayashi H; Hozumi T; Kondo T Gan To Kagaku Ryoho; 2004 Sep; 31(9):1324-30. PubMed ID: 15446551 [TBL] [Abstract][Full Text] [Related]
33. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296 [TBL] [Abstract][Full Text] [Related]
34. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY; J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494 [TBL] [Abstract][Full Text] [Related]
35. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105 [TBL] [Abstract][Full Text] [Related]
36. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. Schütte J; Kellner R; Seeber S Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Blum RH; Edmonson J; Ryan L; Pelletier L Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S238-40. PubMed ID: 8453706 [TBL] [Abstract][Full Text] [Related]
38. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Lashkari A; Chow WA; Valdes F; Leong L; Phan V; Twardowski P; Kapoor N; Molina A; Al-Kadhimi Z; Frankel P; Somlo G Anticancer Res; 2009 Aug; 29(8):3281-8. PubMed ID: 19661346 [TBL] [Abstract][Full Text] [Related]
39. A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients. Huuhtanen RL; Wiklund TA; Blomqvist CP; Böhling TO; Virolainen MJ; Tribukait B; Andersson LC Br J Cancer; 1999 Nov; 81(6):1017-21. PubMed ID: 10576659 [TBL] [Abstract][Full Text] [Related]
40. Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review. Hsieh CL; Chang TC; Lai CH; Jung SM; Chou HH Gynecol Oncol; 2004 Sep; 94(3):854-7. PubMed ID: 15350389 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]